Predicting Ebola Severity: A Clinical Prioritization Score for Ebola Virus Disease
Overview
Tropical Medicine
Authors
Affiliations
Background: Despite the notoriety of Ebola virus disease (EVD) as one of the world's most deadly infections, EVD has a wide range of outcomes, where asymptomatic infection may be almost as common as fatality. With increasingly sensitive EVD diagnosis, there is a need for more accurate prognostic tools that objectively stratify clinical severity to better allocate limited resources and identify those most in need of intensive treatment.
Methods/principal Findings: This retrospective cohort study analyses the clinical characteristics of 158 EVD(+) patients at the GOAL-Mathaska Ebola Treatment Centre, Sierra Leone. The prognostic potential of each characteristic was assessed and incorporated into a statistically weighted disease score. The mortality rate among EVD(+) patients was 60.8% and highest in those aged <5 or >25 years (p<0.05). Death was significantly associated with malaria co-infection (OR = 2.5, p = 0.01). However, this observation was abrogated after adjustment to Ebola viral load (p = 0.1), potentially indicating a pathologic synergy between the infections. Similarly, referral-time interacted with viral load, and adjustment revealed referral-time as a significant determinant of mortality, thus quantifying the benefits of early reporting as a 12% mortality risk reduction per day (p = 0.012). Disorientation was the strongest unadjusted predictor of death (OR = 13.1, p = 0.014) followed by hiccups, diarrhoea, conjunctivitis, dyspnoea and myalgia. Including these characteristics in multivariate prognostic scores, we obtained a 91% and 97% ability to discriminate death at or after triage respectively (area under ROC curve).
Conclusions/significance: This study proposes highly predictive and easy-to-use prognostic tools, which stratify the risk of EVD mortality at or after EVD triage.
Metta E, Mohamed H, Kusena P, Nyamhanga T, Bahuguna S, Kakoko D BMC Public Health. 2024; 24(1):2766.
PMID: 39390413 PMC: 11465839. DOI: 10.1186/s12889-024-20305-2.
A Framework for Assessing the Impact of Outbreak Response Immunization Programs.
Delport D, Sanderson B, Sacks-Davis R, Vaccher S, Dalton M, Martin-Hughes R Diseases. 2024; 12(4).
PMID: 38667531 PMC: 11048879. DOI: 10.3390/diseases12040073.
Mapping of susceptibility loci for Ebola virus pathogenesis in mice.
Schafer A, Marzi A, Furuyama W, Catanzaro N, Nguyen C, Haddock E Cell Rep. 2024; 43(5):114127.
PMID: 38652660 PMC: 11348656. DOI: 10.1016/j.celrep.2024.114127.
Metagenomic surveillance uncovers diverse and novel viral taxa in febrile patients from Nigeria.
Oguzie J, Petros B, Oluniyi P, Mehta S, Eromon P, Nair P Nat Commun. 2023; 14(1):4693.
PMID: 37542071 PMC: 10403498. DOI: 10.1038/s41467-023-40247-4.
Jaspard M, Mulangu S, Juchet S, Serra B, Dicko I, Lang H EClinicalMedicine. 2022; 54:101699.
PMID: 36263398 PMC: 9574409. DOI: 10.1016/j.eclinm.2022.101699.